1 January 2023 false No description of principal activity Taxfiler 2024.5 true 08804774business:PrivateLimitedCompanyLtd2023-01-012023-12-31 088047742022-12-31 088047742023-01-012023-12-31 08804774business:AuditExemptWithAccountantsReport2023-01-012023-12-31 08804774business:FilletedAccounts2023-01-012023-12-31 088047742023-12-31 08804774business:Director12023-01-012023-12-31 08804774business:Director22023-01-012023-12-31 08804774business:RegisteredOffice2023-01-012023-12-31 088047742022-12-31 08804774core:WithinOneYear2023-12-31 08804774core:WithinOneYear2022-12-31 08804774core:ShareCapitalcore:PreviouslyStatedAmount2023-12-31 08804774core:ShareCapitalcore:PreviouslyStatedAmount2022-12-31 08804774core:SharePremiumcore:PreviouslyStatedAmount2023-12-31 08804774core:SharePremiumcore:PreviouslyStatedAmount2022-12-31 08804774core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-12-31 08804774core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2022-12-31 08804774core:PreviouslyStatedAmount2023-12-31 08804774core:PreviouslyStatedAmount2022-12-31 08804774business:SmallEntities2023-01-012023-12-31 08804774countries:EnglandWales2023-01-012023-12-31 08804774core:ComputerEquipment2023-01-012023-12-31 08804774core:ComputerEquipment2022-12-31 08804774core:ComputerEquipment2023-12-31 08804774business:OrdinaryShareClass12023-01-012023-12-31 08804774business:OrdinaryShareClass12022-01-012022-12-31 088047742022-01-012022-12-31 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 08804774 (England and Wales)
Neubourg Pharma (UK) Limited Unaudited accounts for the year ended 31 December 2023
Neubourg Pharma (UK) Limited Unaudited accounts Contents
Page
- 2 -
Neubourg Pharma (UK) Limited Company Information for the year ended 31 December 2023
Directors
Mr G McGlynn Mr T Neubourg
Company Number
08804774 (England and Wales)
Registered Office
75 SPRINGFIELD ROAD CHELMSFORD ESSEX CM2 6JB ENGLAND
Accountants
Harden & Co Chartered Certified Accountants Maelstrom House Taylors Hill Chilham Kent CT4 8BZ
- 3 -
Neubourg Pharma (UK) Limited Statement of financial position as at 31 December 2023
2023 
2022 
Notes
£ 
£ 
Fixed assets
Tangible assets
45 
60 
Current assets
Cash at bank and in hand
77 
5,688 
Creditors: amounts falling due within one year
(144,942)
(145,375)
Net current liabilities
(144,865)
(139,687)
Net liabilities
(144,820)
(139,627)
Capital and reserves
Called up share capital
100 
100 
Share premium
239,900 
239,900 
Profit and loss account
(384,820)
(379,627)
Shareholders' funds
(144,820)
(139,627)
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 10 April 2024 and were signed on its behalf by
Mr G McGlynn Director Company Registration No. 08804774
- 4 -
Neubourg Pharma (UK) Limited Notes to the Accounts for the year ended 31 December 2023
1
Statutory information
Neubourg Pharma (UK) Limited is a private company, limited by shares, registered in England and Wales, registration number 08804774. The registered office is 75 SPRINGFIELD ROAD, CHELMSFORD, ESSEX, CM2 6JB, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover represents the value, net of VAT and discounts, of goods provided to customers and work carried out in respect of services provided to customers.
Tangible fixed assets policy
Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
25% reducing balance
Going concern
These Accounts have been prepared on a going concern basis as the directors have given an assurance that the company will be supported as needed by directors' loans.
4
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 1 January 2023
1,596 
At 31 December 2023
1,596 
Depreciation
At 1 January 2023
1,536 
Charge for the year
15 
At 31 December 2023
1,551 
Net book value
At 31 December 2023
45 
At 31 December 2022
60 
- 5 -
Neubourg Pharma (UK) Limited Notes to the Accounts for the year ended 31 December 2023
5
Creditors: amounts falling due within one year
2023 
2022 
£ 
£ 
Taxes and social security
- 
14,441 
Loans from directors
142,292 
129,584 
Accruals
2,650 
1,350 
144,942 
145,375 
6
Share capital
2023 
2022 
£ 
£ 
Allotted, called up and fully paid:
100 Ordinary shares of £1 each
100 
100 
7
Average number of employees
During the year the average number of employees was 1 (2022: 1).
- 6 -